October 21, 2014
The area of diagnosis and therapy for neuroendocrine tumors (NETs) is rapidly evolving. Procedures that have been available in Europe for many years are currently translated to clinical practice in the United States. These include peptide receptor radiotherapy (PRRT) and Ga-68–labeled somatostatin receptor peptide PET scans, available now through clinical trials in the US.
SNMMI and the North American Neuroendocrine Tumor Society (NANETS) held their first joint symposium at the NANETS Annual Meeting on October 10,2014, in Nashville, Tenn., to provide an in-depth review of the clinical utility of the nuclear medicine technologies for NETs.
The organizers, Drs. Andrei Iagaru and Pam Kunz from Stanford University, designed a comprehensive program that covered the history of somatostatin receptor imaging, current and future developments, a critical review of PRRT in current clinical trials, and the integration of PRRT into routine clinical care.
The symposium was well attended and sparked significant discussion about improving the standard of care for NETs and revising the exclusion/inclusion criteria for future clinical trials. Since the area of nuclear medicine plays a significant role in the field of NETs, both SNMMI and NANETS hope to continue this collaboration in the future.